• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Medical Tubing and Extrusion

Medical tubing and extrusion technologies

  • Catheters
  • Components
    • Connectors
    • Needles and Injections
    • Seals
    • Tubing Components
  • Manufacturing
    • Coatings
    • Extrusions
    • Machining
    • Injection Molding
    • Insert molding
    • Tools
  • Materials
    • Advanced Materials
    • Silicone
  • Research & Development
  • Suppliers

Cardiovascular Systems, Chansu Vascular Technologies partner to develop drug-coated balloons

February 5, 2021 By Danielle Kirsh

cardiovascular-systems-logoCardiovascular Systems recently announced that it has partnered with Chansu Vascular Technologies to develop a new drug-coated balloon technology.

Through the partnership, Cardiovascular Systems and Chansu Vascular Technologies will develop peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems will provide milestone-based financing to Chansu Vascular Technologies for the development of the drug-coated balloons. The deal also includes an acquisition option agreement in which Cardiovascular Systems will have exclusive rights and obligations to acquire the company upon completion of key technical and clinical milestones in the development program.

“This partnership is consistent with our strategic vision to develop an innovative portfolio of new products. We believe these next generation DCBs will complement our current and growing portfolio of products for the treatment of complex coronary and peripheral disease. We are thrilled to be working with CVT in this partnership and are extremely confident that Dr. Marco and his team’s extensive past DCB experience will prove invaluable in developing these next generation DCBs,” Cardiovascular Systems’s chief medical officer Ryan Egeland said in a news release.

Drug-coated balloons are used as a percutaneous interventional treatment option for femora-popliteal lesions in patients who have peripheral artery disease. The balloons are also increasingly recognized for their potential in complex coronary artery disease, according to Cardiovascular Systems. They can be used in in-stent restenosis, small vessels and bifurcation lesions for sustained anti-restenotic efficacy without the limitations of permanent implants.

The active drug (Everolimus) in Chansu Vascular Technologies’s drug coated balloon technology acts as a cytostatic agent to reduce tissue hyperplasia and associated restenosis. It has a proven history of safety and efficacy in coronary drug-eluting stent applications, according to the company.

“The CVT DCBs will be designed to capitalize on the proven long-standing anti-restenotic benefits of everolimus for the treatment of patients with cardiovascular lesions. This collaboration enables us to develop a new class of DCBs that we believe will improve patient outcomes,” Chansu Vascular Technologies founder Philippe Marco said.

 

Filed Under: Catheters, Coatings, Implants, Product Development Tagged With: Cardiovascular Systems, Chansu Vascular Technologies

Primary Sidebar

DeviceTalks Tuesdays

DeviceTalks Tuesdays
MDO ad

Stay Current

Need Medical Tubing news in a minute?
We Deliver!

Medical Tubing + Extrusion newsletter get you caught up on all the mission critical news you need in medical tubing. Sign up today.

Enews Sign up

Sponsored Content

A new way to access scientific papers?

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website

Footer

Inv Logo

MASSDEVICE MEDICAL NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech 100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Souring
R&D World

Medical Tubing & Extrusion

Subscribe to our e-newsletter
Advertise with us
About
Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS